论文部分内容阅读
目的:观察氟桂利嗪治疗脑血栓形成的临床疗效。方法:选择2015年5月至2017年2月期间收治的60例脑血栓形成患者,随机分为对照组(28例)和观察组(32例)。对照组采用血栓通治疗,观察组在对照组基础上增加氟桂利嗪治疗,比较两组治疗效果情况,并评估用药安全性。结果:观察组脑血栓形成治疗总有效率(93.75%)显著高于对照组(78.57%),组间差异p<0.05。观察组不良反应发生率(9.38%)与对照组(10.71%)比较无显著差异(p>0.05)。结论:脑血栓形成患者采用氟桂利嗪治疗效果可靠,其不良反应风险较低,临床应用价值较高。
Objective: To observe the clinical efficacy of flunarizine in the treatment of cerebral thrombosis. Methods: Sixty patients with cerebral thrombosis who were admitted between May 2015 and February 2017 were randomly divided into control group (n = 28) and observation group (n = 32). The control group was treated with Xueshuantong. The observation group was given flunarizine on the basis of the control group. The treatment effect was compared between the two groups, and the safety of medication was evaluated. Results: The total effective rate of the treatment group (93.75%) in the observation group was significantly higher than that in the control group (78.57%), with a difference of p <0.05. The incidence of adverse reactions in the observation group (9.38%) was not significantly different from that in the control group (10.71%) (p> 0.05). Conclusion: Flunarizine treatment in patients with cerebral thrombosis is reliable, with low risk of adverse reactions and high clinical value.